scholarly journals Correlation Between Serum Uric Acid and Renal Function in Patients With Stable Coronary Artery Disease and Type 2 Diabetes

2014 ◽  
Author(s):  
Chen
Keyword(s):  
Type 2 Diabetes ◽  
Coronary Artery Disease ◽  
Renal Function ◽  
Uric Acid ◽  
Coronary Artery ◽  
Serum Uric Acid ◽  
Stable Coronary Artery Disease ◽  
Artery Disease

Serum Uric Acid Levels, but Not rs7442295 Polymorphism of SCL2A9 Gene, Predict Mortality in Clinically Stable Coronary Artery Disease

2021 ◽  
Vol 46 (5) ◽  
pp. 100798
Author(s):  
Chiara Mozzini ◽  
Domenico Girelli ◽  
Angela Setti ◽  
Jacopo Croce ◽  
Filippo Stefanoni ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Uric Acid ◽  
Coronary Artery ◽  
Serum Uric Acid ◽  
Stable Coronary Artery Disease ◽  
Artery Disease

2208-PUB: Prevalence of Type 2 Diabetes Is Higher in Patients with Heart Failure than in Patients with Stable Coronary Artery Disease

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 2208-PUB
Author(s):  
CHRISTOPH H. SAELY ◽  
ALEXANDER VONBANK ◽  
CHRISTINE HEINZLE ◽  
DANIELA ZANOLIN-PURIN ◽  
BARBARA LARCHER ◽  
...  
Keyword(s):  
Heart Failure ◽  
Type 2 Diabetes ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Stable Coronary Artery Disease ◽  
Patients With Heart Failure ◽  
Artery Disease

scholarly journals Hyperuricemia and Hypertension, Coronary Artery Disease, Kidney Disease: From Concept to Practice

2020 ◽  
Vol 21 (11) ◽  
pp. 4066 ◽  
Author(s):  
Mélanie Gaubert ◽  
Thomas Bardin ◽  
Alain Cohen-Solal ◽  
François Diévart ◽  
Jean-Pierre Fauvel ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Renal Function ◽  
Uric Acid ◽  
Coronary Artery ◽  
Kidney Disease ◽  
Serum Uric Acid ◽  
Elevated Serum ◽  
Renal Diseases ◽  
Increased Risk ◽  
Artery Disease

Since the publication of the Framingham Heart Study, which suggested that uric acid should no longer be associated with coronary heart disease after additional adjustment for cardiovascular disease risk factors, the number of publications challenging this statement has dramatically increased. The aim of this paper was to review and discuss the most recent studies addressing the possible relation between sustained elevated serum uric acid levels and the onset or worsening of cardiovascular and renal diseases. Original studies involving American teenagers clearly showed that serum uric acid levels were directly correlated with systolic and diastolic pressures, which has been confirmed in adult cohorts revealing a 2.21-fold increased risk of hypertension. Several studies involving patients with coronary artery disease support a role for serum uric acid level as a marker and/or predictor for future cardiovascular mortality and long-term adverse events in patients with coronary artery disease. Retrospective analyses have shown an inverse relationship between serum uric acid levels and renal function, and even a mild hyperuricemia has been shown to be associated with chronic kidney disease in patients with type 2 diabetes. Interventional studies, although of small size, showed that uric acid (UA)-lowering therapies induced a reduction of blood pressure in teenagers and a protective effect on renal function. Taken together, these studies support a role for high serum uric acid levels (>6 mg/dL or 60 mg/L) in hypertension-associated morbidities and should bring awareness to physicians with regards to patients with chronic hyperuricemia.

scholarly journals Patients with stable coronary artery disease and type 2 diabetes but without prior myocardial infarction or stroke and THEMIS-like patients: real-world prevalence and risk of major outcomes from the SNDS French nationwide claims database

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Patrick Blin ◽  
Patrice Darmon ◽  
Patrick Henry ◽  
Estelle Guiard ◽  
Marie-Agnès Bernard ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Type 2 Diabetes ◽  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Major Bleeding ◽  
Stable Coronary Artery Disease ◽  
Composite Outcome ◽  
Claims Database ◽  
Artery Disease

Abstract Aim and hypotheses The THEMIS randomized trial compared ticagrelor plus aspirin versus placebo plus aspirin for patients with stable coronary artery disease and type 2 diabetes mellitus (CAD-T2DM), and without prior myocardial infarction (MI) or stroke. The aim of the study was to quantify the size of the CAD-T2DM population without prior MI or stroke population in a real-world setting, and more specifically populations with similar THEMIS selection criteria (THEMIS-like and THEMIS-PCI-like populations), as well as their risk of major outcomes in current practice. Methods A 2-year follow-up cohort study included all CAD-T2DM without MI/stroke prevalent patients on January 1st, 2014 in the SNDS French nationwide claims database. The THEMIS-like population concerned those ≥ 50 years of age with similar THEMIS inclusion and exclusion criteria. Prevalence was standardized to the European population. The cumulative incidence function was used to estimate the incidence of clinical outcomes (MI, ischemic stroke, and major bleeding according to the TIMI classification) with death as competing risk, and the Kaplan–Meier estimate for all-cause death and a composite outcome of MI, stroke and all-cause death. Results From a population of about 50 million adults, the prevalence of CAD-T2DM without MI/stroke, THEMIS-like and THEMIS-PCI-like populations was respectively at 6.04, 1.50 and 0.27 per 1000 adults, with a mean age of 72.7, 72.3 and 70.9 years and less comorbidities and diabetic complications for the THEMIS-like and THEMIS-PCI-like population. The 2-year cumulative incidence was respectively 1.7%, 1.3% and 1.6% for MI, 1.7%, 1.5% and 1.4% for stroke, 4.8%, 3.1% and 2.9% for major bleeding, 13.6%, 9.7% and 6.8% for all-cause death, and 16.2%, 12.0% and 9.5% for the composite outcome. Conclusion THEMIS-like prevalence was estimated at 1.50 per 1,000 adults, representing about a quarter of CAD-T2DM without MI/stroke patients, and 0.27 per 1000 adults for the THEMIS-PCI-like populations. In current French practice, the median age of both these populations was about 5–6 years older than in the THEMIS trial, with a 2-year incidence of major outcomes between two or four time above the ones of the placebo arm of the THEMIS trial using very close definitions. Registration No. EUPAS27402 (http://www.ENCEPP.eu).

Sign in / Sign up

Export Citation Format

Share Document